Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
Amphastar P (AMPH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/08/2025: AMPH (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $32.4
1 Year Target Price $32.4
| 2 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 4.7% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.08B USD | Price to earnings Ratio 8.28 | 1Y Target Price 32.4 |
Price to earnings Ratio 8.28 | 1Y Target Price 32.4 | ||
Volume (30-day avg) 6 | Beta 0.76 | 52 Weeks Range 22.43 - 53.95 | Updated Date 07/8/2025 |
52 Weeks Range 22.43 - 53.95 | Updated Date 07/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.76 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 19.38% | Operating Margin (TTM) 21.87% |
Management Effectiveness
Return on Assets (TTM) 7.6% | Return on Equity (TTM) 19.9% |
Valuation
Trailing PE 8.28 | Forward PE - | Enterprise Value 1493249483 | Price to Sales(TTM) 1.47 |
Enterprise Value 1493249483 | Price to Sales(TTM) 1.47 | ||
Enterprise Value to Revenue 2.04 | Enterprise Value to EBITDA 5.76 | Shares Outstanding 47139100 | Shares Floating 35990691 |
Shares Outstanding 47139100 | Shares Floating 35990691 | ||
Percent Insiders 23.68 | Percent Institutions 72.67 |
Upturn AI SWOT
Amphastar P
Company Overview
History and Background
Amphastar Pharmaceuticals, Inc. was founded in 1996. It is a specialty pharmaceutical company that focuses on developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation products. The company initially focused on developing and marketing generic injectable products and has expanded into proprietary products and biosimilars.
Core Business Areas
- Finished Pharmaceutical Products: Develops, manufactures, and markets generic and proprietary injectable and inhalation products, including critical care and other specialty injectables.
- API Products: Develops and manufactures Active Pharmaceutical Ingredients (APIs) for both internal use and sale to third parties.
- Insulin: Develops and manufactures Insulin and this contributes to the future of the business.
Leadership and Structure
The leadership team includes the CEO, CFO, and other key executives. The company operates with a functional organizational structure, encompassing R&D, manufacturing, sales, and marketing divisions.
Top Products and Market Share
Key Offerings
- Enoxaparin Sodium Injection: A generic version of Lovenox, used to prevent and treat blood clots. Competitors include Novartis (through its Sandoz division) and Teva Pharmaceuticals. Market share is difficult to pinpoint precisely but Enoxaparin products are a major source of revenue for Amphastar.
- Epinephrine Injection: Used for emergency treatment of allergic reactions (anaphylaxis). Competitors include Mylan (Viatris) and Teva Pharmaceuticals. Market share is significant in the generic epinephrine market.
- Glucagon: Used for diabetes to treat hypoglycemia. Market share is significant and is growing with new product approval.
Market Dynamics
Industry Overview
The pharmaceutical industry is highly regulated and competitive. Demand for generic injectables is driven by cost containment efforts and patent expirations. There is a growing market for Insulin and biosimilars.
Positioning
Amphastar P is positioned as a specialty pharmaceutical company with a focus on difficult-to-manufacture injectable products. Its competitive advantages include its manufacturing capabilities and expertise in complex generics.
Total Addressable Market (TAM)
The TAM for generic injectables is estimated to be in the billions of dollars annually. Amphastar P's TAM is a subset of this, focused on its specific product categories. The TAM for insulin is even larger.
Upturn SWOT Analysis
Strengths
- Strong manufacturing capabilities
- Expertise in complex generics
- Focus on niche markets
- Vertical integration through API manufacturing
Weaknesses
- Reliance on a limited number of products
- Exposure to pricing pressures
- Dependence on regulatory approvals
- High R&D costs
Opportunities
- Expanding into new therapeutic areas
- Developing biosimilars
- Acquiring complementary businesses
- Penetrating emerging markets
Threats
- Increased competition from other generic manufacturers
- Patent challenges
- Changes in regulatory requirements
- Pricing pressures from payers
Competitors and Market Share
Key Competitors
- VTRS
- TEVA
- NVS
Competitive Landscape
Amphastar P competes with larger pharmaceutical companies with broader product portfolios. Its advantages include its focus on niche markets and its manufacturing capabilities.
Major Acquisitions
Nordic Group B.V.
- Year: 2022
- Acquisition Price (USD millions): 170
- Strategic Rationale: Expand commercial presence in Europe and broaden product portfolio with approved and pipeline products.
Growth Trajectory and Initiatives
Historical Growth: Amphastar P has experienced growth driven by the launch of new products and increased sales of existing products. Real financials will highlight this
Future Projections: Analyst estimates for future growth depend on new product launches, market conditions, and competitive dynamics. Financial sites such as Yahoo Finance highlight this information
Recent Initiatives: Recent strategic initiatives may include acquisitions, partnerships, and investments in R&D. This information is best acquired by looking at the company's releases.
Summary
Amphastar Pharmaceuticals is a specialty pharmaceutical company with a focus on difficult-to-manufacture injectables. It has strong manufacturing capabilities and expertise in complex generics but is exposed to pricing pressures and regulatory risks. Recent acquisitions and strategic initiatives aim to drive future growth, but competition from larger pharmaceutical companies remains a key challenge. Strong fundamentals with risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be based on individual research and consultation with a financial advisor. Market share estimates are approximate and may vary.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Amphastar P
Exchange NASDAQ | Headquaters Rancho Cucamonga, CA, United States | ||
IPO Launch date 2014-06-25 | Co-Founder, President, CEO, Chief Scientific Officer & Director Dr. Yongfeng Zhang Ph.D. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 2028 | Website https://www.amphastar.com |
Full time employees 2028 | Website https://www.amphastar.com | ||
Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging, as well as Albuterol Sulfate inhalation aerosol. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.